We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Isarna Therapeutics Raises Euro 13 Million from New and Current Investors
News

Isarna Therapeutics Raises Euro 13 Million from New and Current Investors

Isarna Therapeutics Raises Euro 13 Million from New and Current Investors
News

Isarna Therapeutics Raises Euro 13 Million from New and Current Investors

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Isarna Therapeutics Raises Euro 13 Million from New and Current Investors"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Isarna Therapeutics GmbH has announced that it has raised Euro 13 million (USD 17.8 Mio) in equity from new private investor AT NewTec and current investors, MIG-managed funds.

Proceeds will be used to advance the company's pipeline of next generation oligonucleotides that inhibit various isoforms of TGF-β, a key molecular pathway implicated in mechanisms used by cancer cells to evade immune system detection and to aid in tumor proliferation.

"This financing supports our position as the leaders in utilizing TGF-β as a unique target for cancer immunotherapy and enables us to continue the rapid development of our pipeline toward the clinic," said Dr. Philippe Calais, Chief Executive Officer at Isarna Therapeutics. "We are fortunate to have the continued commitment from MIG, our largest shareholder, and welcome the new investment from AT NewTec.”

“MIG is convinced that an immunotherapy approach to treating cancer has the potential to change the paradigm of current standard of care,” added Dr. Matthias Kromayer, Managing Director of MIG Verwaltungs AG. “We have great confidence in both Isarna’s pioneering approach to leveraging TGF-β and the company’s management.”

Advertisement